Search

Fitusiran

[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety.

Ponatinib

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

Teniposide

Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. … Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.

Doripenem

, resulting in a premature termination of the trial. … Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen.

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … binding at the ATP domain of the epidermal growth factor receptor family kinase domains.

Luteinizing hormone

Bufexamac

It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, … Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac.

Oxyphenonium

It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem] … A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine.

Telisotuzumab vedotin

[L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting

Padeliporfin

[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.